Morgan Stanley Cuts 3SBIO (01530) Target Price to HK$34, Keeps "Overweight" Rating

Stock News
Apr 14

Morgan Stanley has released a research report incorporating 3SBIO's (01530) 2025 performance forecast. The report lowers the sales forecast and milestone payment expectations for the company's core commercial product TPIAO, primarily due to the impact of USD depreciation against the RMB. Consequently, Morgan Stanley has revised down its revenue forecasts for 3SBIO for the years 2026 to 2028 by 5%, 7%, and 6% respectively. The report also adjusts the product gross margin forecast based on recent trends and modifies the operating expense ratio. Earnings per share forecasts for the same period have been lowered by 8.3%, 14.5%, and 12.4% respectively. The target price has been reduced from HK$38 to HK$34, while the "Overweight" rating is maintained.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10